Zentalis Pharmaceuticals, Inc.
ZNTLBiotechnology
$1.99−3.40%As of Oct 29vs prior close
- Market cap
- $195.3M
- P/E (TTM)
- –
- From 52W high
- −69.89%
- EPS (YE25)
- -$1.91
- Revenue (YE25)
- $0
- Dividend yield
- 0.00%
Nomior Score
41
Steady ProfileSpeculativeBottom 30% of the scored universe
Growth—
Quality35
Value37
Momentum70
Resilience34
Growth
$0revenue, YE25
YE22 $0YE25 $0
Connections
Revenue to profitQ4 YE24
The operating loss was 186% of revenue.
Who owns it
2funds